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The in vitro activation of splenocytes or PBL with rIL-2 generates a population
of cytotoxic effector cells with broad antitumor reactivity (1-4) . These lymphokine-
activated killer (LAK)' cells have been suggested to be useful for the adoptive im-
munotherapy of metastatic tumors in animal models and in man (5-7) . LAK cells
have the ability to bind and lyse virtually any tumor cell, but do not lyse normal
cells (1, 4, 7-10) . Although LAK cells have gained much attention due to this prop-
erty, very little is known about the nature of the surface structures used by LAK
cells to recognize and lyse tumors .
Recent evidence suggests that the majority of cells with LAK activity are derived
from the NK/large granular lymphocyte(LGL) subset oflymphocytes . Many studies
indicate that LAK progenitor cells from the mouse have a phenotype characteristic
ofNK cells, as they express asialo GMt, do not express L3T4 or Lyt-2, and as some
express Thy-1 (11-14) . Studies using human lymphocytes have suggested that LAK
cell progenitors are mainly LGL with a CD3- , CD16+ , NKH1+, phenotype (3, 9,
10, 15-17) . In the rat, the majority of LAK progenitor cells have been described
as being LGL that express an asialo GMt+, OK8+ , Lam', 0X19- , 0X6 - , W3/25- ,
Ig- phenotype (8, 18-20) .
While the majority of evidence suggests that LAK progenitor cells are derived
from LGL/NK cells, a number of groups have presented evidence that LAK cells
can be generated from otherlymphoid compartments . C133', NKH1 + lymphocytes
have been demonstrated in human peripheral blood and have been associated with
non-MHC-restricted cytotoxicity . Further, these cells have been used to produce clones
with NK-like activity (21-23) . Other studies suggest that LAK activity can be gener-
ated from a variety of subpopulations, including CD4+, CD8+, and B cells (24) .
Recent studies using cells from human thymus have shown that LAK activity can
be generated from thymocytes of either a CD3`, CD4 - , CD8 - or CD3- , CDl - ,
CD2' phenotype (18, 25-29) .
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LAK effector cells have been shown to be very similar in phenotype to their pro-
genitor cells. In human, they are mainly LGL that express a CD3 - , NKH1+,
CD16+ phenotype (3, 9, 10, 16, 17). Mouse LAK cells are characteristically asialo
GM,+, L3T4- , Lyt-2- and may or may not express Thy-1 (11-14). Rat LAK cells
are mainly LGL expressing an asialo GM, + , 0X8+ , Lam', 0X6+, 0X19 - , W3/25- ,
Ig- phenotype (8, 18-20).
While there are several NK-specific markers available in the various species, none
is without limitations for the study of the relationship of NK and LAK cells. In
humans, CD16 (Leu-11) has been found on virtually all NK cells (30), but its expres-
sion decreases on LAK cells cultured 2-3 d in rIL-2 (unpublished data). NKH1
(Leu-19) is found on almost all NK cells, but it is also detected on a small percentage
of CD3+ T cells (31, 32). In the mouse and rat, asialo GM, is expressed on NK
cells and LAK cells but it is also expressed on a variety of other subpopulations
(14, 33-36). The marker 0X8 is expressed on rat NK and LAK cells, but it is also
on -30% of rat T cells (18, 20, 37). Lam 1 is specific for rat NK cells, but not all
NK cells (N50%) express this marker (20). For these reasons, new markers that are
specific for NK cells and that are expressed on LAK cells generated from NK cells,
will be ofgreat use for the characterization and enumeration ofprogenitorand effector
populations of LAK cells.
Vujanovic et al. (38) recently developed a simple, reproducible technique for the
isolation of large numbers of highly purified (>98%) populations of rat splenocytes
with activated NK phenotype (0X6+, 0X8+, Lam', Asialo GMI+, 0X19 - , W3/25 - ,
Ig-), LGL morphology, and LAK cytolytic activity (38). In isolating these cells,
use is made of the observation that LGL selectively adhere to plastic surfaces after
stimulation with rIL-2. Because of this property, these cells are termed adherent
LAK (A-LAK) cells.
To explore the relationship of NK and LAK cells, and their function, we have
generated a series of hybridomas secreting mAbs against A-LAK cells that affect
the cytolytic activity or proliferation of A-LAK cells. In this report, we describe the
production of a hybridoma that secretes an mAb (3 .2 .3 ; IgGlk) that recognizes a
triggering structure expressed on rat LGL/NK cells and LAK cells generated from
this subpopulation (A-LAK).
Materials and Methods
Reagents.
￿
mAbs for rat NK cells, T cells, macrophages, and B cells were obtained from
Seratec Limited (Oxon, UK). R-phycoerythrin (RPE)- and FITC-conjugated goat anti-
mouse Igs were obtained from Organon Teknika-Cappel (Malvern, PA) . Human rIL-2 was
the generous gift ofCetus Corp. (Emeryville, CA). Anti-HLA-DR (IgGl), used as an isotype
control, was kindly provided by Dr. M. Trucco (Pittsburgh Cancer Institute). Na25'Cr04 was
purchased from New England Nuclear (Boston, MA). Tissue culture medium (RPMI 1640),
FCS, and antibiotics (penicillin/streptomycin) were obtained from Gibco Laboratories (Grand
Island, NY).
Animals, Cells from Selected Organs, and Cell Lines.
￿
Fischer 344 male rats (F344, 75-100 g)
were obtained from Taconic Farms, Inc., (Germantown, NY) and maintained in a specific
pathogen-free animal facility for at least 2 wk before use. BALB/c female mice were obtained
from The Jackson Laboratory(Bar Harbor, ME) and maintained in a specific pathogen-free
animal facility. CRNK-16, an F344 LGL leukemia; MADB106, an F344 rat mammary ade-
nocarcinoma; YAC-1, a mouse T cell lymphoma; P815, a mouse mastocytoma; Daudi, a human
B lymphoblast cell line; K562, a human erythroleukemia; and U937, a human histiocyticCHAMBERS ET AL.
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lymphoma, were maintained as monolayers or stationary suspension cultures in RPMI 1640
medium containing 10% FCS, antibiotics, and t,-glutamine (complete medium) at 37°C in
a humidified 5% C02 atmosphere. Cell cultures were passaged as required to maintain the
cultures in a log phase ofgrowth. Lymphocytes from various organs were obtained by aseptic
removal of the organs with subsequent isolation of cells by mincing (if required) followed
by centrifugation on Ficoll or Percoll density gradient medium.
Preparation ofNK andA-LAK Cells.
￿
NK and A-LAK cells were prepared as described (38).
Briefly, splenic lymphocytes were isolated by density gradient centrifugation of splenocytes
on Ficoll-Hypaque (p = 1 .077) (Pharmacia Fine Chemicals, Piscataway, NJ) followed by pas-
sage over nylon wool columns. These cells were used as effector cells in NK assays. For A-
LAK cells, nylon wool nonadherent lymphocytes were cultured at 2.0 x 106/ml in complete
medium containing 5 x 10' M 2-ME and 1,000 U/ml rIL-2 in 75-cm2 tissue culture flasks
(Corning Glass Works, Corning, NY). After stimulation with rIL-2, LGL selectively adhere
to the plastic surface. After 48 h, the nonadherent cells were decanted and removed from
the supernatant by centrifugation. The supernatant was then filtered and added back to the
adherent cells (conditioned medium). The adherent cells were then cultured for an addi-
tional 3-4 d. Effector cells isolated in this fashion express markers and morphology charac-
teristic of rat NK cells (18-20, 38).
mAbs.
￿
mAbs were produced as previously described (39). Supernatants ofthe fusion prod-
ucts ofP3.653 and spleen cells of BALB/c mice, hyperimmunized with rat A-LAK cells, were
screened for their effect on cytolytic activity of rat A-LAK cells. The supernatant from one
well enhanced cytotoxicity against P815 target cells. These cells, which produce an IgGI product,
were cloned three times by limiting dilution and designated 3 .2.3. Hybridoma supernatants
and ascites fluid from hybridoma-bearing BALB/c mice were used in these studies.
Cytotoxicity Assays. Cytotoxicity was measured using a standard 4-h "Cr release
microcytotoxicity assay in 96-well, round-bottomed microtiter plates (Costar, Cambridge,
MA) as previously described (40). YAC-1 or P815 target cells (2-3 x 106) were labeled with
100 /ACi of Na251Cr04 for 60 min, washed three times, resuspended at 10'/ml in complete
medium . Target cells were then seeded into 96-well plates at 5 x 10;/well in 50 Wl . 10-20
ld of mAb supernatants were then added to each well. Suspensions of A-LAK effector cells
were then added to triplicate wells to give various E/T ratios in a final volume of 200 td.
After incubation for 4 h at 37°C, the plates were centrifuged (100 g) and 100 'al ofsupernatant
was removed from each well and counted in a gamma counter to determine specific cytotox-
icity. The percent cytotoxicity was determined by the formula: percent cytotoxicity = 100
x ((experimental release - spontaneous release)/(total release - spontaneous release)l.
Assays of antibody-dependent cellular cytotoxicity (ADCC) were performed as described
above, with the additional steps ofpretreating the effector cells with F(ab')2 fragments of mAb
3 .2.3 and target cells with dilutions of specific antiserum for 30 min at 37°C followed by
two washes.
Target Cell Binding Assays.
￿
mAbs were tested for their effects on conjugate formation of
effector cells and target cells essentially as described (40, 41). A minor modification of this
technique included first labeling of the A-LAK cells with fluorescein diacetate (FDA) so that
these cells could be easily distinguished from the target cells under UV microscopy. Prelimi-
nary experiments suggest that this labeling does not interfere with A-LAK cytolytic function
(data not shown). After washing, 5 x 10' FDA-labeled A-LAK cells were preincubated with
antibody for 15 min at 4°C. 5 x 10' target cells in 0.5 ml of complete medium were added
to the mAb-treated A-LAK cells and the mixture centrifuged at 400 g for 5 min. Cells were
then incubated 30 min to allow binding. The cell mixture was then suspended by gentle aspi-
ration. A drop of the suspended cells was then added to glass slides and the number of con-
jugates determined microscopically. 200 A-LAK cells were counted and the percentage of
cells bound to one or more target cells calculated using the formula: percent binding cells
= 100 x (number of FDA labeled cells bound to one or more targets/total number of FDA
labeled cells).
FACS Analysis and Cell Sorting
￿
For surface marker analysis, 2-3 x 10' cells were placed
in 12 x 75-mm plastic tubes in 0.1 ml of staining buffer (PBS, pH 7.3, 0.1% sodium azide,
2% FCS). Antibody or serum was added (1 :20-1 :100 final dilution) for 30 min at 4°C. mAb137 6
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3.2.3 was tested (both intact and F[ab']2 fragments) at dilutions up to 1 :200,000. The cells
were then washed twice and resuspended with RPE- or FITC-conjugated F(ab')2 fragments
of the appropriate second antibody (see figure legends; Cappel Laboratories, Malvern, PA).
After 30 min of incubation at 4°C, the cells were washed twice and analyzed for fluorescent
staining using a FACStar flow cytometer (Becton Dickinson & Co., Mountain View, CA).
Two-color analysis was performed using directly labeled FITC-F(ab')2 fragments of mAb
3.2.3 afterstaining with antibody to rat lymphocyte subsets and RPE-conjugated second an-
tibody. FACS analysis of highly purified blood LGL and polymorphonuclear leukocytes (PMN)
(Fig. 2) were performed by Dr. CraigW. Reynolds (Biological Response Modifiers Program,
NCI, Frederick, MD). For sorting, fresh nylonwool nonadherent splenic lymphocytes were
stained as above except that the staining buffer contained no sodium azide.
Preparation ofF(ab)2 Fragments of mAb 3.2.3.
￿
F(ab')2 fragments of mAb 3.2.3 (ascites) were
prepared as described (42). mAb 3.2.3 (1 .75 mg/ml), in PBS with 0.1 M citrate, was incubated
for 8 h (37°C) at pH 3.5 with 25 pg/ml pepsin (Sigma Chemical Co., St. Louis, MO). This
preparation was dialyzed against HBSS to restore neutral pH and was analyzed by SDS-
PAGE. F(ab')2 fragments were the only large molecular mass product (ti100 kD) and no fur-
ther purification was done. FITC-F(ab')2 fragments of the preparation were made using 0.06
mg FITC/mg protein in 0.2 M carbonate/bicarbonate buffer (pH 9.4). Unbound FITC was
removed by passing the preparation over G-10 Sephadex.
Assay of Exocytosis Induced by mAb 3.2.3.
￿
Assays to determine BLTesterase secretion (as
a marker ofgranule exocytosis) were performed using a modification of the method described
by Takayama et al. (43). Briefly, affinity-purified mAb 3 .2.3 was immobilized in 96-well mi-
crotiter plates (MC2000; Dynatech Laboratories, Inc., Alexandria, VA) at various dilutions
in 0 .1 M carbonate/bicarbonate buffer (pH 8.0) (100 A1/aliquot) by incubation at 4°C for
18 h. After incubation, the solution was removed and the wellswere washed with RPMI 1640/10
mM Hepes/5% FCS. BLTesterase secretion was measured using 106 A-LAK cells in 0.1 ml
RPMI 1640/10 mM Hepes/5% FCS in the presence or absence of stimulus (mAb 3.2 .3 in
the wells). After 4 h of incubation at 37°C under 5% C02 tension, cells were resuspended
by gentle pipetting and centrifuged at 100 g for 5 min. 50-Al aliquots of supernatant were
used to assay enzyme activity. Total cellular content of BLTesterase was determined using
0.1% Triton X-100 solubilized cells. Data are presented as a mean specific percentage ofenzy-
matic activity released, which was calculated by the formula: percent release = 100 x [(E
- S)/(T - S)]; where E equals the number of enzyme units in the supernatant of the ex-
perimental well, S equals the number of enzyme units in the supernatants of the wells with
no stimuli, and T equals the totalnumber of units of BLTesterase in A-LAK cells per well.
Culture medium (0.05 ml) was mixed with 200 141 of N-a-benzyloxycarbonyl-L-lysine thio-
benzyl ester(BIT) solution (0.2 mM BIT, 0.22 mM 5,5'-dithio-bis-2-nitrobenzol acid [I7TNB])
in PBS (pH 7.2). The mixture was incubated 120 min at 37°C and the reaction stopped by
adding 5 A1 of 0.1 M PMSF, which is dissolved in DMSO. Absorbance was measured in a
microtiter ELISA reader (Dynatech Laboratories, Inc.) at 412 nm.
Cell Surface Iodination and Immunoprecipitation.
￿
A-LAK cells (5.0 x 10') were washed three
times in PBS and pelleted by centrifugation (400 g for 5 min). 100 Al of lactoperoxidase and
glucose oxidase-coupled enzymobeads (Bio-Rad Laboratories, Richmond, CA) were then
added to the pellet. Subsequently, 20 A1 of lactoperoxidase (1 mg/ml in PBS) and 100 1,1 of
2 x PBS were added to the pellet, followed by 20 A1 of '251 (50 mCi/ml; New England Nu-
clear). The peroxide-forming reaction was then begun by the addition of 20 Al of a 1% solu-
tion of(3-n-glucose in PBS. The cells were then gently resuspended and incubated at ambient
temperature for 15 min with periodic mixing. The peroxide-forming step was then repeated
a second time. After washing, the cells were lysed at 4°C in PBS containing I% Triton X-100,
0.1 % SDS, and a cocktail ofprotease inhibitorsincluding PMSF (1 mM), leupeptin (1 Ag/ml),
pepstatin A (5 gg/ml), aprotinin (5 Ag/ml), and 5 mM EDTA at pH 7.4. Cell debris was
removed by centrifugation at 100,000 g for 30 min.
Before immunoprecipitation, the cell extract was precleared with Sephadex G-10 (vol/vol)
with lysis buffer followed by three passages over BSA-coupled Sephadex beads. Total counts
were then determined in cold ethanol precipitates.
Immunoprecipitation was carried out using25,ul of mAb 3.2.3-coupled beads incubatedwith 10' cold ethanol precipitate counts at 4°C for 4 h on a rotating wheel. As controls, 10'
cold ethanol precipitable counts were also incubated, as above, with 25,ul of beads coupled
to BSA or irrelevant mAb. Antigen was stripped from the affinity matrix by treatment with
buffer containing 0.25 M Tris, 2% SDS, 1% glycerol, and 1% 2-ME for the reduced sample.
For nonreduced samples, the buffer was the same except for a lack of 2-ME. Samples were
then subjected to electrophoresis on 3-20% gradient SDS-PAGE slab gels at 20 mA/slab.
The proteins were fixed in the gels with a solution of TCA/methanol followed by a solution
of ethanol/acetic acid/H20. The gels were then washed in deionized water and placed in a
solution of Fluorohance (Research Products International Corp., Mount Prospect, IL) sup-
plemented with 10% glycerol to prevent cracking. Gels were then dried and placed under
preflashed x-ray film for 2 wk.
Results
Tissue andCellularDistribution oftheE,bitolbeIdentified by nzAb 3.2.3.
￿
The expression
of the epitope identified by mAb 3.2.3 on various normal tissues of F344 rats, as
well as a panel oftumors ofmouse and rat origin, was determined by flow cytometry.
The epitope identified by mAb 3.2.3 was found to be expressed on 94% of LGL
isolated from peripheral blood (95% LGL) (Fig. 1 a) and 93% of the LGL isolated
from spleen (data not shown). The staining pattern on LGL was not homogeneous
(two peaks consistently apparent). This marker was also expressed in an homoge-
neous staining pattern on 96% of A-LAK cells (activated NK); on 83% of F344
PMN; and on 84% of CRNK-16 (an NK-like, LGL leukemia in F344 rats) (Fig.
1 b and Table 1). The marker was also expressed on -10% of PBL, spleen cells,
and peritoneal cells, and its expression correlated with the percentage of LGL present
in these preparations (Table 1) . The epitope identified by mAb 3.2.3 was present
on 2 17o of bone marrow and lymph node cells but was totally absent on thymocytes.
Finally, a small population of peritoneal exudate cells (PECs) (N10%) stained posi-
tively with mAb 3 .2.3 and this corresponded to the percentage of LGL in this prepa-
ration (Table 1). Nevertheless, we performed two-color analyses on purified popula-
tions of rat macrophages using the rat macrophage specific marker 0X41 and mAb
CHAMBERS ET AL.
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FIGURE 1.
￿
Expression of the epitope recognized by mAb 3.2.3 on F344 rat LGL and PMN.
F344 rat LGL were isolated from peripheralblood on a discontinuous Percoll gradient to a purity
ofX95% as measured by Giemsa staining. PMN were also isolated from F344 rat blood on Per-
coll, and were 385% neutrophils.1378
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TABLE I
Correlation of the Expression of the Epitope Identified by mAb 3.2.3 and
Percentage of LGL in Various Tissues and Cell Lines
3.2.3 and foundthat macrophagesdid notcoexpressOX41 and3.2.3 (data not shown).
Tumor cells, including YAC-1, P815, and MADB106, were negative for the expres-
sion of 3.2.3.
Coexpression of 3.2.3 with Lymphocyte Subsets Identified by Other mAbs.
￿
To determine
the coexpression of3.2.3 with mAbs identifying other rat lymphocyte subsets, two-
color analyses were performed with fresh, nonadherent splenocytes using markers
associated with rat T cells (0X19 and 0X8), NKcells (0X8), B cells (0X6), and mac-
rophages (0X6 and 0X41) (Fig. 2). As shown in Fig. 2 A, 0X6 (la-like) and 3.2.3
stain discrete populations of fresh splenic lymphocytes. The 3.2.3+ cells constitute
9.6% of the total population (Fig. 2 A, quadrant 4), and none ofthese cells were
OX6' (quadrant 2). Staining these cells with 0X8 (cytotoxic T cell and NK cell
specific) and 3.2.3 (Fig. 2 B) demonstrated that 25.9% ofthe cells were 0X8+ (quad-
rants 1 and 2). Virtually all of the 3.2.3+ cells were in the double-stained popula-
tion, i.e., coexpressed 0X8 (Fig. 2 B, quadrant 2). The OX8' cells could clearly be
divided into the T cell compartment (Fig. 2 B, quadrant 1, 17.2%) and NK cell
compartment (quadrant 2, 8.2%) by double stainingwith 3.2.3. Confirmatory results
were demonstrated by double staining with OX19 (pan T marker) and 3.2.3 (Fig.
2 C). OX19 staining was demonstrated on 68.3% ofthese cells (quadrant 1). None
ofthese cells coexpressed OX19 and 3.2.3 (quadrant 2). Staining ofspleen cells with
0X41 (macrophage and endothelial cell specific) and 3.2.3 also showed that these
two regions were not coexpressed on any cells (Fig. 2 D).
Correlation of NK Activity and Staining with mAb 3.2.3 by Positive Cell Sorting.
￿
NK
cell lytic function was assayed in unsorted and in positive and negative cell sorts
after staining of nonadherent splenocytes with mAb 3.2.3 (Fig. 3). The unsorted
cells were 35% positive for expression ofthe 3.2.3 epitope and contained NK cells
as defined by cytotoxicity against YAC-1 target cells. The 3.2.3+ cells (96% pure)
werehighly cytolyticallyactive againstYAC-1 target cells, and thepositive sort resulted
in a doubling ofcytotoxic activity expressed in the unsorted cells, on a cell to cell
Cell tissue Percent LGL mAb 3.2 .3
Fresh LGL 95 95*
A-LAK 96 96
Bone marrow <1 1
Thymus <1 0
Blood/PBL 8 11
Spleen 8 11
Lymph node 2 2
Peritoneal cells 10 12
CRNK-16 88 84
YAC-1 0 < 1
P813 0 <1
MADB106 0 6
PMN 0 83
* Percent positive staining cells.w s
200
s
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FIGURE 2.
￿
Two-color FAGS analysis of nonadherent splenic lymphocytes comparing staining
of mAb 3.2.3 with 0X6, 0X8, 0X19, and0X41. F344 ratsplenocytes were isolated from spleens
by Ficoll density gradient centrifugation and passage over nylon wool columns. Cells were 101 /0
LGL as determined by Giemsa staining. Staining by quadrant: 1, RPE- ; 2, FITC -/RPE- ; 3,
-/-; 4, FITC- .
basis. The cells in the 3.2 .3 - sort (99.0% pure) were not cytotoxic against YAC-1
target cells at any E/T ratio assayed.
Expression of the Epitope Recognized by mAb 3.2.3 on F344 RatA-LAK Cells at Various
Time Points After Stimulation with rIL-2.
￿
Expression by A-LAK cells of the epitope
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identified by mAb 3.2.3 was analyzed by flow cytometry at various time points after
stimulation with HL-2 (Fig. 4). In Fig. 4, peak a represents the intensity of staining
of A-LAK cells by mAb 3 .2 .3 after 24 h in culture with HL-2. More than 93% of
the cells expressed the epitope at this time point, with a mean fluorescence of 43 .7.
After 48 h ofculture (peak b), 92.8% ofthe A-LAK cells were positive for the expres-
sion of this marker, at a mean fluorescence of 147 . After 120 h of culture (peak c),
94.1% of the A-LAK cells expressed this marker with a mean fluorescence of 871.
A-LAK populations were homogeneous (stained as a single peak) at each of the time
points tested.
C
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￿
fr
0 lot 102 103
FLUORESCENCE INTENSITY IA.U.I
FIGURE 3 .
￿
Correlation of NK
cell activity and staining with
mAb 3 .2.3 by positive cell
sorting. Nylon wool nonadherent
splenic lymphocytes from F344
rats were stained with mAb
3.2 .3 and sorted on a FACStar
(Becton Dickinson & Co.). NK
cytolytic activity against YAC-
1 target cells was determined
in a 4-h "Cr release assay in
the unsorted, the 3 .2.3', and
3.2 .3- cell sorts.
FIGURE 4.
￿
Expression ofthe epitope identified
by mAb 3.2 .3 on F344 rat A-LAK cells after
culture in rIL-2. A-LAK cells were analyzed
for expression oftheepitope identified by mAb
3.2.3 after 24, 48, and 120 h ofculture in the
presence of 1,000 U/ml rIL-2. At 24 h (peak
a), A-LAK were 93% positive with a mean
fluorescence intensity 43.7. After 48 and 120
hours (peaks b and c, respectively), A-LAK
cultures were 92.8% and 94.1% positive for
3.2.3. Mean fluorescence intensity at 48 h was
147 and increased to 871 at 120 h.CHAMBERS ET AL.
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TABLE II
Effects of mAb 3.2.3 on NK Cell and A-LAK Cell Cytotoxicity
Against Selected Target Cells
Percent specific cytotoxicity as determined in a 4-h 5'Cr release assay. NK
assays were performed using a 100:1 E/T ratio and A-LAK assays were per-
formed using a 3:1 E/T ratio.
" Dilutions of mAb 3.2.3 (hybridoma supernatant) were present throughout the
assay. Anti-HLA-DR (IgGI, isotype control) did not modulate cytotoxicity
against any target tested. Further, numerous other isotype-matched, anti-
A-LAK cell-specific mAbs also did not modulate cytotoxicity against any tar-
get tested.
Selective Enhancement ofCytotoxicity Induced by mAb 3.2.3.
￿
mAb 3.2.3 was screened
for its effect on cytolytic activity of NK and A-LAK cells against various tumors.
As indicated in Table II, mAb 3.2.3 selectively enhanced the cytolytic activity of
NK and A-LAK cells against P815 but not YAC-1 or MADB106 target cells. The
enhancement oflysis of P815 by mAb 3.2.3 was dose dependent over a wide range
ofdilutions. Cytotoxicity by NK cells was enhancedagainstP815 target cells atdilu-
tions up to 10-4. A-LAK cell cytotoxicity against P815 target cells was boosted at
dilutions as high as 10-6.
EffectsofmAb 3.2.3on Formation ofA-LAKCell/Tumor Target Cell Conjugates.
￿
To ex-
plore the feasible basis for the selective augmentation ofcytotoxicity against P815
target cells, the effects ofmAb 3.2.3 on conjugate formation between A-LAK cells
and P815 or YAC-1 tumor target cells were determined (Fig. 5). Effector and target
cells (1:1 E/T ratio) were incubated inthe presence ofvariousdilutions ofmAb 3.2.3.
Dilutions of10-1 and 10-2 caused a 100% and 120% increase in conjugates formed
between A-LAK cells and P815 target cells, respectively. A dilution of 10-3 caused
an increase of 38% in conjugates formed. In contrast, the number of conjugates
formed betweenA-LAK cells andYAC-1 target cellswas not affectedby thepresence
ofthe mAb. While the results suggest that mAb 3.2.3 facilitates conjugate forma-
tion, the dilutions that enhance cytotoxicity are several logs (up to 10-6) greaterthan
those that induce an increase in conjugate formation.
Comparison ofInduction ofLysis ofIntact andF(ab')2 Fragments ofmAb 3.2.3 Against a
Panel ofTarget Cells. Preparations ofintact and F(ab')2 fragments ofmAb 3.2.3 were
compared for their ability to cause an enhancement ofcytotoxicity ofA-LAK cells
against a panel oftarget cells expressing (P815, Daudi, and U937) orlackingexpres-
sion (YAC-1, MADB106, and K562) ofa receptor for the Fc portion ofIg (Fig. 6).
Intact mAb 3.2.3 caused an increase in A-LAK cell cytotoxicity against FcR+ target
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NK
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cells
MADB106 P815
A-LAK
YAC-1
cells
MADB106
Control 1* 40 6 18 43 28
mAb dilutionsl
10-1 4 46 6 56 43 24
10-2 13 49 4 59 45 29
10-3 12 41 7 63 44 26
10-4 8 29 6 65 43 22
10-5 2 34 4 43 45 29
10-6 3 33 4 32 51 31
10-1 0 33 5 22 44 301382
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FIGURE 5.
￿
Effects ofmAb3.2.3
on conjugate formation of A-
LAK cells and P815 or YAC-1
target cells. FITC-labeled A-
LAKcells andunlabeledtarget
cells (1:1 ratio) were incubated
with various dilutions of 3.2.3
for30 minat 4°C. 200A-LAK
cells were countedandtheper-
centage ofcells boundto one or
more target cells wascalculated.
Anti-HLA-DR (IgGl, isotype
control) had no effect on con-
jugate formation.
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FIGURE 6.
￿
Inductionof lysis (reverse ADCC)by 3.2.3 IgG and F(ab')2 against apanel of target
cells. F344 A-LAK cells were mixed with the indicated target cells (10:1 E/T ratio) in the pres-
ence or absence of 100 ng/ml purified 3.2.3 IgG or F(ab')2. Cytotoxicity was determined after
a4-h assay. Anti-HLA-DR(IgGl, isotype control) had no effect on lytic function vs. YAC-1 on
P815. Further, numerous (IgG) isotype-matched anti-A-LAK cell-specific mAbs also had no
modulating effect on cytotoxicity.1 30
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FIGURE 7 .
￿
ImmobilizedmAb
3.2.3 induces exocytosis ofBLT
esterase. Affinity-purifiedmAb
3.2 .3 was incubated at various
dilutions for 18 h at 4°C in mi-
crotiter plates (model II ; Im-
mulon; Dynatech Laboratories,
Inc. ; Chantilly, VA) . A-LAK
cells (100 Al at 10 7/ml) were
then added to each well and in-
cubated 4 h . BLTesterase ac-
tivity was determined in 50-ttl
aliquots of those supernatants
as described (43) . Maximum
releasable BLTesterase was
determined in 0.1% Triton
X-100-solubilized cells. Back-
ground release wasdetermined
in supernatants ofA-LAK cells
incubated in the absence of
mAb 3.2 .3 .
cells P815, Daudi, and U937 but had no effect on cytotoxicity against YAC-1,
MADB106, or K562 . F(ab')2 fragments of mAb 3.2.3 did not affect cytotoxicity
against FCR+ or FcR- target cells .
Immobilized mAb 3.2.3 Induces Exocytosis of BLTEsterase by A-LAK Cells .
￿
Using a
modification of the technique described by Takayama et al . (43), mAb 3.2.3 was
assayed for its ability to trigger exocytosis of the granule-associated enzyme BLT
esterase (Fig. 7) . Variousconcentrations ofaffinity-purifiedmAb 3.2.3 were incubated
in microtiter plates (model II ; Immulon; Dynatech Laboratories, Chantilly, VA) for
18 h at 4°C. The wells were then washed and 100 , .1 ofa suspension ofA-LAK cells
(101/ml) added to wells . The plates were then incubated 4 h. BLTesterase was
FIGURE 8 .
￿
SDA-PAGE gel of "II-labeled protein identified by mAb
3.2 .3 .1384
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demonstrated in supernatants of these cultures with peak release (N40%) being in-
duced at 12.5 ng/ml. Both lower (3 .13 ng/ml) and higher (100 ng/ml) concentrations
of antibody induced less enzyme release.
SDS-PAGE Analysis of mAb 3.2.3 Immunoprecipitates.
￿
SDS-PAGE analysis of 1251_
labeled 3 .2 .3 immunoprecipitates yielded a single band of -30 kD molecular mass
under reducing conditions (Fig. 8). When analyzed under nonreducing conditions,
there was a single band of -60 kD. These results suggest that the structure recog-
nized by mAb 3.2.3 is a 60-kD dimer composed of two 30-kD chains.
Discussion
In this report, we describe an mAb ofmouse origin (mAb 3.2.3; IgGlk) that recog-
nizes a triggering structure expressed on rat NK cells and A-LAK cells. This epitope
is also expressed on PMN. We have defined the specificity of mAb 3.2.3 for the NK
cell subset of mononuclear cells by a variety ofcriteria, including its pattern of tissue
distribution, a comparison of its expression with other markers for subpopulations
of lymphoid cells and monocytes, a correlation of expression of the epitope recog-
nized by this antibody and LGL morphology, and by positive cell sorting for NK
cell cytolytic function. The epitope recognized by mAb 3.2.3 is expressed on >95 17o
of blood and splenic LGL; on >80% of blood PMN; on N10 0 Io of PBL splenocytes,
and peritoneal cells; and on 1-2% of bone marrow and lymph node cells. Thymo-
cytes were <1% positive for this marker. CRNK-16, an F344 rat LGL leukemia ex-
pressing NK activity, was also positive for mAb 3.2.3 (>84%). In all cell prepara-
tions and tissues examined, the expression of the epitope identified by mAb 3.2.3
correlated with LGL morphology, with the exception of PMN . By two-color FRCS
analysis of fresh splenic lymphocytes, the cells stained by mAb 3 .2 .3 were identified
as NK cells. Cells positive for mAb 3 .2 .3 were also positive for 0X8 (NK, CTL),
but were negative for 0X6 (la-like; macrophages and B cells), 0X19 (pan T marker)
and 0X41 (macrophages and endothelial cells) . Cell sorting of nonadherent splenic
lymphocytes into mAb 3 .2 .3+ and 3 .2.3 - populations demonstrated that the NK
cytolytic activity was totally contained in the 3.2.3' sort. These data suggest that
mAb 3 .2 .3 represents the best LGL/NK cell marker available in the rat system, as
other markers, such as asialo GM1 and 0X8, are also expressed on other subpopu-
lations including T cells (14, 18, 20, 33, 37). Monoclonal and polyclonal antibodies
to laminin have been shown to identify a subset of LGL/NK cells in mice and rats
(20, 44, 45). The mAb Lam-1, which reacts with the B2 subunit of laminin, identifies
ti50% of peripheral blood LGL/NK cells and has been shown to inhibit cytolytic
function of NK cells. Although the cell and tissue distribution of the epitopes recog-
nized by mAbs 3 .2.3 and Lam-1 are similar (i.e., LGL/NK cells), several features
distinguish these antibodies. These include : (a) the expression of the epitope recog-
nized by mAb 3 .2 .3 on LGL/NK cells is at a much higher intensity than that recog-
nized by mAb Lam-1 (350 relative fluorescence intensity units [R. F. I.] vs. 60 R .
F. I. ; reference 20); (b) the inhibitory effects on cytotoxicity of mAb Lam-1 vs. the
boosting effects of mAb 3.2.3; and (c) the expression of the Lam-1 epitope on -50%
of LGL/NK cells while -100To express the epitope recognized by mAb 3 .2 .3 . Since
virtually all LGL/NK cells react with mAb 3.2.3, this antibody will be useful as
a pan-LGL/NK cell marker in rats, and the heterogeneity of staining by Lam-1 and
0X8 suggest that those antibodies may be useful for the sublettingof LGL/NK cells.
mAb 3 .2.3 was produced by immunizing mice with rat A-LAK cells (rIL-2-activatedCHAMBERS ET AL.
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NK cells) and then screening hybridomas for their effects on A-LAK cell cytotox-
icity. Interestingly, mAb 3.2.3 induces a selective increase in cytotoxicity of both
NK and A-LAK cells against certain tumor target cells. Using a panel of tumor
target cells to screen for this effect, it was determined that FcR+ target cells in-
cluding P815, Daudi, and U937 were lysed more efficiently in the presence of mAb
3.2 .3 . However, FcR- target cells including YAC-1, MADB106, and K562 were not.
This effect was not observed with either FcR+ or FcR- target cells when using F(ab')2
fragments of the antibody. Assays of conjugate formation demonstrated a selective
increase in conjugation ofA-LAK cells with P815 target cells, but this occurred only
at high concentrations ofantibody, while boosting ofcytotoxicity occurred at several
logs greater dilution of the antibody.
The selective boosting of cytolytic activity by intact mAb 3.2.3 and the tissue dis-
tribution (LGL and PMN) of the epitope recognized by mAb 3 .2 .3 are similar to
data reported for antibodies to CD16 (Leu-lla/NKP-15, Leu-11b/3G8, Leu-1101373.1)
in humans (30, 46-48). As with mAb 3 .2 .3, levels of cytotoxicity and conjugate for-
mation by NK cells could be increased by antibody to CD16 using FcR+ target cells
(P815) if the mAb was ofthe appropriate isotype for the target cell FcR (e.g., IgGl)
(49). The increase in cytotoxicity is suggested to be, in effect, a reverse ADCC reac-
tion and is termed "induction" (49). Induction has also been demonstrated using
antibodies to other triggering structures including CD2 and CD3 (49-53).
While some of our data suggest chat the triggering structure identified by mAb
3.2.3 may be analogous to CD16, there is also evidence that it may recognize a different
structure. First, unlike Leu-11a staining of purified human A-LAK cells, which
decreases after their culture with rIL-2 (Whiteside, T L. and R . B. Herberman,
personal communication), the epitope identified by this antibody increased on rat
A-LAK cells after culture in rIL-2. Secondly, the antigen immunoprecipitated by
mAb 3 .2.3 from 1251-labeled A-LAK cells appeared as a 60-kD band in nonreduced
gels and as a 30-kD band in reduced gels . This is different than the size reported
for CD16, which appeared as a broad band at a molecular mass of45-70 kD (54-56) .
Preliminary data (not shown) suggest that mab 3 .2.3 does not block functions medi-
ated through the FcR, such as ADCC. A further examination of this and the ability
of mAb 3.2 .3 to block binding of aggregated Ig and EA rosette formation are cur-
rently under way.
In this report, we describe the first mAb produced against a purified population
of cells with LAK activity. It has previously been shown that the cells with LAK
cytolytic function, produced by the selective adherence technique, develop from the
NK compartment (38), and the fact that this antibody was reactive against both
A-LAK and NK cells further confirms this observation. The boosting of cytolytic
function of A-LAK and NK cells by mAb 3 .2.3, and the induction of BLTesterase
release by immobilized mAb 3.2.3, are strong evidence that this antibody recog-
nized a triggering structure. Further, this antibody recognized a dimeric surface
structure on NK and A-LAK cells that has characteristics unlike CD2 or CD16,
and may, in fact, be a unique triggering structure.
Summary
To study the cellular structures involved in NK and lymphokine-activated killer
(LAK) cell function, we have produced a panel of mAbs that modulate the cytolytic
function of a population of cells with LAK activity that derive from large granular1386
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lymphocyte (LGL)/NK cells (adherent LAK [A-LAK] cells). In this report, we de-
scribe an mAb (3 .2.3 ; IgGlk) that recognizes a triggering structure that is expressed
on rat LGL/NK cells and A-LAK cells. This epitope is also expressed on polymor-
phonuclear leukocytes (PMN). The expression ofthe epitope identified by mAb 3.2.3
increased progressively on A-LAK cells after culture in the presence of rIL-2 . mAb
3 .2 .3 enhanced the cytolytic activity of NK and A-LAK cells against FCR` target
cells, but not FcR - target cells. However, this effect was not induced by F(ab')2 frag-
ments of 3 .2.3 . This antibody also induced the release ofN-a-benzyloxycarbonyl-L-
lysine thiobenzy esteresterase by A-LAK cells. These data suggest that the epitope
identified by mAb 3 .2 .3 is on a triggering structure expressed on rat NK cells and
A-LAK cells. The expression of the epitope recognized by mAb 3 .2 .3 on LGL/NK
cells and PMN suggests that this structure may be analogous to that identified by
the anti-CD16 (-FcR) mAbs. However, the molecule immunoprecipitated by mAb
3 .2 .3 was a 60-kD dimer composed of two 30-kD chains. These data suggest that
mAb 3.2.3 recognizes a unique triggering structure. As mAb 3.2.3 is the first anti-
body recognizing a determinant with functional significance, selectively expressed
on both rat NK cells and A-LAK cells, it will be a useful tool for the study of NK
cell ontogeny and function, and the development of cells with LAK activity from
the NK cell compartment.
The authors would like to express great appreciation to Dr. Craig W. Reynolds for the anal-
ysis of 3 .2.3 staining of fresh, purified LGL and PMN and to Dr. Joseph Phillips for a most
helpful discussion of the results.
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